RIGL logo

RIGL
Rigel Pharmaceuticals

12,466
Mkt Cap
$599.08M
Volume
418,083.00
52W High
$52.24
52W Low
$16.43
PE Ratio
1.71
RIGL Fundamentals
Price
$32.43
Prev Close
$31.77
Open
$32.80
50D MA
$30.43
Beta
1.33
Avg. Volume
399,681.46
EPS (Annual)
$19.48
P/B
1.52
Rev/Employee
$1.69M
$705.27
Loading...
Loading...
News
all
press releases
Ritholtz Wealth Management Acquires 72,999 Shares of Rigel Pharmaceuticals, Inc. $RIGL
Ritholtz Wealth Management increased its holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 961.3% in the fourth quarter, according to its most recent Form 13F filing with the...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire...
PR Newswire·12d ago
News Placeholder
Hennion & Walsh Asset Management Inc. Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGL
Hennion & Walsh Asset Management Inc. bought a new stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 52,189 shares of the biotechnology company...
MarketBeat·17d ago
News Placeholder
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology Rigel Announces Publication of Final ARROW...
PR Newswire·19d ago
News Placeholder
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six analysts that are currently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendat...
MarketBeat·21d ago
News Placeholder
Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?
Madrigal (MDGL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·23d ago
News Placeholder
Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Lowered to "Hold" at Wall Street Zen
Wall Street Zen cut Rigel Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday...
MarketBeat·1mo ago
News Placeholder
Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Down - What's Next?
Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Down - Time to Sell...
MarketBeat·2mo ago
News Placeholder
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of "Hold" from Brokerages
Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) have been assigned a consensus rating of "Hold" from the seven research firms that are covering the company, Marketbeat Ratings...
MarketBeat·2mo ago
News Placeholder
Rigel Pharmaceuticals Q4 Earnings Call Highlights
Rigel Pharmaceuticals (NASDAQ:RIGL) detailed record commercial performance for the fourth quarter and full year 2025, while outlining plans to pursue additional in-licensing opportunities and advance...
MarketBeat·2mo ago
<
1
2
...
>

Latest RIGL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.